Evaluating Dato-DXd and Durvalumab for Treating Certain Types of Breast Cancer
Official title: A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Run by AstraZeneca · NCT06112379 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new combination treatment for certain types of breast cancer to see if it works better than the standard therapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1728 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | durvalumab, pembrolizumab, chemotherapy |
| Locations | 355 sites (Daphne, Alabama and 354 other locations) |
| Trial ID | NCT06112379 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed Stage II or III TNBC or hormone receptor-low/HER2-negative breast cancer.
✕Probably not a fit
Patients with a history of prior invasive breast malignancy or those with distant disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase III clinical trial is a multicenter, global study that compares the effectiveness and safety of neoadjuvant Dato-DXd combined with durvalumab against neoadjuvant pembrolizumab plus chemotherapy in patients with untreated triple-negative breast cancer (TNBC) or hormone receptor-low/HER2-negative breast cancer. Participants will receive either treatment followed by adjuvant therapy to assess the primary outcomes of pathologic complete response (pCR) and event-free survival (EFS). The study aims to determine if the new combination therapy offers superior results compared to the standard treatment.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients with aggressive forms of breast cancer.
How similar studies have gone: Other studies have shown promising results with similar immunotherapy approaches in breast cancer, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant must be ≥ 18 years, at the time of signing the ICF. * Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer * ECOG PS of 0 or 1 * Provision of acceptable tumor sample * Adequate bone marrow reserve and organ function * Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and aligned with protocol requirements. Exclusion criteria: * History of any prior invasive breast malignancy * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before randomization. * active or prior documented autoimmune or inflammatory disorders. * Evidence of distant disease. * Clinically significant corneal disease. * Has active or uncontrolled hepatitis B or C virus infection. * Known HIV infection that is not well controlled. * Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections. * Known to have active tuberculosis infection * Mean resting corrected QTcF interval \> 470 ms obtained from ECG * Uncontrolled or significant cardiac disease. * History of non-infectious ILD/pneumonitis * Has severe pulmonary function compromise * Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer * For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant. * Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer. * Concurrent use of systemic hormone replacement therapy or oral hormonal contraception
Where it's running
-
Research Site
Daphne, Alabama, United States Recruiting -
Research Site
Goodyear, Arizona, United States Recruiting -
Research Site
Tucson, Arizona, United States Recruiting -
Research Site
Jonesboro, Arkansas, United States Recruiting -
Research Site
Rogers, Arkansas, United States Recruiting -
Research Site
Bakersfield, California, United States Recruiting
Show 44 more locations
-
Research Site
Fullerton, California, United States Recruiting -
Research Site
Los Angeles, California, United States Recruiting -
Research Site
Orange, California, United States Recruiting -
Research Site
Santa Barbara, California, United States Recruiting -
Research Site
Santa Rosa, California, United States Recruiting -
Research Site
Torrance, California, United States Recruiting -
Research Site
Van Nuys, California, United States Recruiting -
Research Site
Aurora, Colorado, United States Recruiting -
Research Site
Fort Collins, Colorado, United States Recruiting -
Research Site
Longmont, Colorado, United States Recruiting -
Research Site
Bridgeport, Connecticut, United States Recruiting -
Research Site
New Haven, Connecticut, United States Recruiting -
Research Site
Fort Myers, Florida, United States Recruiting -
Research Site
Jacksonville, Florida, United States Recruiting -
Research Site
Saint Petersburg, Florida, United States Recruiting -
Research Site
West Palm Beach, Florida, United States Recruiting -
Research Site
Atlanta, Georgia, United States Recruiting -
Research Site
Atlanta, Georgia, United States Recruiting -
Research Site
Chicago Ridge, Illinois, United States Recruiting -
Research Site
Des Moines, Iowa, United States Recruiting -
Research Site
Edgewood, Kentucky, United States Recruiting -
Research Site
Louisville, Kentucky, United States Recruiting -
Research Site
Baton Rouge, Louisiana, United States Recruiting -
Research Site
Annapolis, Maryland, United States Recruiting -
Research Site
Boston, Massachusetts, United States Recruiting -
Research Site
Detroit, Michigan, United States Recruiting -
Research Site
Grand Rapids, Michigan, United States Recruiting -
Research Site
Traverse City, Michigan, United States Recruiting -
Research Site
Burnsville, Minnesota, United States Recruiting -
Research Site
Minneapolis, Minnesota, United States Recruiting -
Research Site
Columbia, Missouri, United States Recruiting -
Research Site
Omaha, Nebraska, United States Recruiting -
Research Site
Henderson, Nevada, United States Recruiting -
Research Site
Camden, New Jersey, United States Recruiting -
Research Site
East Brunswick, New Jersey, United States Recruiting -
Research Site
New Brunswick, New Jersey, United States Recruiting -
Research Site
Santa Fe, New Mexico, United States Recruiting -
Research Site
New York, New York, United States Recruiting -
Research Site
Charlotte, North Carolina, United States Recruiting -
Research Site
Durham, North Carolina, United States Recruiting -
Research Site
Blue Ash, Ohio, United States Recruiting -
Research Site
Canton, Ohio, United States Recruiting -
Research Site
Eugene, Oregon, United States Recruiting -
Research Site
Portland, Oregon, United States Recruiting
+305 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Dato-DXd with or without Durvalumab to standard chemotherapy for advanced triple-negative breast cancer
This study is testing if a new treatment called Dato-DXd, with or without another drug called durvalumab, can help people with advanced triple-negative breast cancer live longer without their cancer getting worse compared to standard chemotherapy.
-
Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer
A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.
-
Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer
This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.
-
SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer
This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.
-
Using mistletoe extract with pembrolizumab for treating triple negative breast cancer
This study is testing if adding mistletoe extract to pembrolizumab can help adults with triple negative breast cancer feel better after surgery.
-
New treatment approach for high-risk early-stage breast cancer
This study is testing a new combination of treatments for people with high-risk early-stage triple-negative breast cancer to see if it can shrink tumors more than the usual treatment before surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.